Search results
Showing 601 to 615 of 2208 results for guidelines
This quality standard covers increasing vaccine uptake among children and young people aged under 19 in groups and settings that have low immunisation coverage. It describes high-quality care in priority areas for improvement.
View quality statements for QS145Show all sections
Sections for QS145
- Quality statements
- Quality statement 1: Follow-up invitations
- Quality statement 2: Offering outstanding vaccinations
- Quality statement 3: Recording vaccinations
- Quality statement 4: Checking immunisation status at specific educational stages
- Quality statement 5: Checking immunisation status of young offenders and offering outstanding vaccinations
- Update information
- About this quality standard
Evidence-based recommendations on 12 standard quality house dust mite sublingual lyophilisate (SQ-HDM SLIT; Acarizax) for treating allergic rhinitis and allergic asthma caused by house dust mites.
COVID-19 rapid guideline: acute kidney injury in hospital (NG175)
This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.
This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.
May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COVID-19 see our guideline on managing COVID-19.
Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA394)
Evidence-based recommendations on evolocumab (Repatha) for treating primary hypercholesterolaemia or mixed dyslipidaemia in adults.
This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.
This guideline covers preventing, identifying and managing latent and active tuberculosis (TB) in children, young people and adults. It aims to improve ways of finding people who have TB in the community and recommends that everyone under 65 with latent TB should be treated. It describes how TB services should be organised, including the role of the TB control board.
Empagliflozin for treating chronic heart failure with reduced ejection fraction (TA773)
Evidence-based recommendations on empagliflozin (Jardiance) for treating chronic heart failure with reduced ejection fraction in adults.
This guideline covers good practice for managing medicines in care homes. It aims to promote the safe and effective use of medicines in care homes by advising on processes for prescribing, handling and administering medicines. It also recommends how care and services relating to medicines should be provided to people living in care homes.
Chronic wounds: advanced wound dressings and antimicrobial dressings (ESMPB2)
Summary of the evidence on advanced wound dressings and antimicrobial dressings for managing chronic wounds to inform local NHS planning and decision-making
Evidence-based recommendations on the bisphosphonates alendronic acid, ibandronic acid, risedronate sodium and zoledronic acid for treating osteoporosis.
Evidence-based recommendations on dabigatran etexilate (Pradaxa) for preventing venous thromboembolism after hip or knee replacement surgery in adults.
View recommendations for TA157Show all sections
COVID-19 rapid guideline: delivery of systemic anticancer treatments (NG161)
September 2023: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COVID-19 see our guideline on managing COVID-19.
Evidence-based recommendations on vortioxetine (Brintellix) for treating major depressive episodes in adults.